Evidence map›Paper›PMID 35422467›Full record

Trial reportMolecular psychiatry2022

Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia.

Samantha V Abram, Brian J Roach, Susanna L Fryer, Vince D Calhoun, Adrian Preda, Theo G M van Erp, Juan R Bustillo, Kelvin O Lim, Rachel L Loewy, Barbara K Stuart and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Ketamine reduces the neural distinction between self- and other-produced affective touch: a randomized double-blind placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Samantha V AbramSierra Pacific Mental Illness Research Education and Clinical Centers, San Francisco Veterans Affairs Medical Center, and the University of California, San Francisco, CA, USA.
Brian J RoachSan Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA.
Susanna L FryerSan Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA.
Vince D CalhounTri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State, Georgia Tech, Emory, Atlanta, GA, 30332, USA.
Adrian PredaDepartment of Psychiatry and Human Behavior, University of California Irvine Medical Center, 101 The City Dr. S, Orange, CA, 92868, USA.
Theo G M van ErpClinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, 5251 California Ave, Irvine, CA, 92617, USA.
Juan R BustilloDepartment of Psychiatry and Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, 87111, USA.ORCID http://orcid.org/0000-0001-8730-8152
Kelvin O LimDepartment of Psychiatry, University of Minnesota, Minneapolis, MN, 55454, USA.ORCID http://orcid.org/0000-0002-2390-7268
Rachel L LoewyDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA, 94143, USA.
Barbara K StuartDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA, 94143, USA.
John H KrystalDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, 06510, USA.ORCID http://orcid.org/0000-0001-6952-1726
Judith M FordSan Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA.ORCID http://orcid.org/0000-0002-6500-6548
Daniel H MathalonSan Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA. daniel.mathalon@ucsf.edu.ORCID http://orcid.org/0000-0001-6090-4974
San Francisco VA Medical Center · USUniversity of California, San Francisco · USGeorgia Institute of Technology · USUniversity of California, Irvine · USUniversity of California, Irvine Medical Center · USUniversity of Minnesota · USUniversity of New Mexico · USYale University · US

Funding

FUNCTION BIRNU24RR021992 · NCRR · UNIVERSITY OF CALIFORNIA-IRVINE · PI POTKIN, STEVEN G · 2006 to 2010
$25.0M
BIO-INFORMATICS RESEARCH NETWORK COORDINATING CENTER (BIRN-CC)U24RR025736 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KESSELMAN, CARL · 2009 to 2011
$15.0M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
NCRR NIH HHS U24 RR021992NCRR NIH HHS U24 RR025736NIMH NIH HHS R01 MH076989
6 · The paper itself

Abstract

N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizophrenia. Resting-state functional magnetic resonance imaging (rsfMRI) studies demonstrate a thalamic dysconnectivity pattern in schizophrenia involving excessive connectivity with sensory regions and deficient connectivity with frontal, cerebellar, and thalamic regions. The NMDAR antagonist ketamine, when administered at sub-anesthetic doses to healthy volunteers, induces transient schizophrenia-like symptoms and alters rsfMRI thalamic connectivity. However, the extent to which ketamine-induced thalamic dysconnectivity resembles schizophrenia thalamic dysconnectivity has not been directly tested. The current double-blind, placebo-controlled study derived an NMDAR hypofunction model of thalamic dysconnectivity from healthy volunteers undergoing ketamine infusions during rsfMRI. To assess whether ketamine-induced thalamic dysconnectivity was mediated by excess glutamate release, we tested whether pre-treatment with lamotrigine, a glutamate release inhibitor, attenuated ketamine's effects. Ketamine produced robust thalamo-cortical hyper-connectivity with sensory and motor regions that was not reduced by lamotrigine pre-treatment. To test whether the ketamine thalamic dysconnectivity pattern resembled the schizophrenia pattern, a whole-brain template representing ketamine's thalamic dysconnectivity effect was correlated with individual participant rsfMRI thalamic dysconnectivity maps, generating "ketamine similarity coefficients" for people with chronic (SZ) and early illness (ESZ) schizophrenia, individuals at clinical high-risk for psychosis (CHR-P), and healthy controls (HC). Similarity coefficients were higher in SZ and ESZ than in HC, with CHR-P showing an intermediate trend. Higher ketamine similarity coefficients correlated with greater hallucination severity in SZ. Thus, NMDAR hypofunction, modeled with ketamine, reproduces the thalamic hyper-connectivity observed in schizophrenia across its illness course, including the CHR-P period preceding psychosis onset, and may contribute to hallucination severity.

Indexed as

KetamineSchizophreniaGlutamatesHallucinationsHumansLamotrigineMagnetic Resonance ImagingReceptors, N-Methyl-D-AspartateGlutamatesKetamineLamotrigineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID35422467
PMCPMC9135621
OpenAlexW4224022576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.